Science News
from research organizations

CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1

Date:
December 1, 2009
Source:
Duke University Medical Center
Summary:
Tests performed by the Centers for Disease Control and Prevention at the request of infectious disease experts have confirmed that isolates from four patients with H1N1 influenza at Duke University Hospital during October and November were found to be resistant to oseltamivir (Tamiflu).
Share:
       
FULL STORY

Tests performed by the Centers for Disease Control and Prevention (CDC) at the request of infectious disease experts at Duke University Medical Center have confirmed that isolates from four patients with H1N1 influenza at Duke University Hospital over the past six weeks were found to be resistant to oseltamivir (Tamiflu).

Two oseltamivir-resistant H1N1 isolates were reported in western North Carolina earlier this summer.

A team of experts from CDC, State of North Carolina Public Health Department, Durham County Health Department, and the Duke Division of Infectious Diseases are now working collaboratively to better understand the nature of these cases.

All four isolates, or samples, were obtained from four patients in an isolated unit of one floor at Duke University Hospital. All four patients were very ill with underlying severely compromised immune systems and multiple other complex medical conditions.

"We're partnering with all of the involved agencies to examine these cases," said Daniel Sexton, MD, professor of medicine and director of the Duke Infection Control Outreach Network (DICON).

"Our extensive investigation thus far has revealed that appropriate infection control procedures have been diligently practiced on this isolated unit, and throughout the hospital, and we have experienced no illness among employees taking care of these patients in the affected unit over this period of time."

According to CDC, patients with oseltamivir-resistant H1N1 have had similar, no more severe, illness than patients with oseltamivir-susceptible virus.

Furthermore, CDC reports that all confirmed cases of oseltamivir-resistant virus to date have been susceptible to zanamivir (Relenza), a second antiviral medication that is indicated for the treatment of H1N1. At this time, CDC does not recommend any changes in antiviral guidance.

There is no evidence these few cases represent a hospital-wide concern. Furthermore, the number of hospitalizations at Duke for H1N1 influenza had declined in early November, consistent with new information recently released by the North Carolina State Department of Health that documents overall declines statewide in hospitalizations, emergency room visits, and other such measures.


Story Source:

The above post is reprinted from materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1." ScienceDaily. ScienceDaily, 1 December 2009. <www.sciencedaily.com/releases/2009/11/091130121941.htm>.
Duke University Medical Center. (2009, December 1). CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1. ScienceDaily. Retrieved July 3, 2015 from www.sciencedaily.com/releases/2009/11/091130121941.htm
Duke University Medical Center. "CDC confirms four new cases of oseltamivir (Tamiflu)-resistant H1N1." ScienceDaily. www.sciencedaily.com/releases/2009/11/091130121941.htm (accessed July 3, 2015).

Share This Page: